Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

99
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
99
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

996
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
996
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

698
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
698
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

2.2K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
2.2K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

396
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of deprescribing for people with life-limiting conditions: A systematic review.

Palliative medicine·2026
Same author

The conceptualisation and measurement of social frailty in older people: an umbrella review.

The Journal of frailty & aging·2025
Same author

Organising general practice for care homes: a multi-method study.

Health and social care delivery research·2025
Same author

Ecological study of the association between the English national vaccination programme and area deprivation inequalities in COVID-19 mortality.

BMJ open·2025
Same author

Which unmet social care needs have the biggest impact on healthy ageing? An analysis of data from the English Longitudinal Study of Ageing.

BMJ open·2025
Same author

Clinical validation of an artificial intelligence-based decision support system for diagnosis and risk stratification of heart failure (STRATIFYHF): a protocol for a prospective, multicentre longitudinal study.

BMJ open·2025

Related Experiment Video

Updated: Apr 26, 2026

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules
05:30

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

19.8K

Drugs for treating urinary schistosomiasis.

Christine V Kramer1, Fan Zhang, David Sinclair

  • 1Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK, L3 5QA.

The Cochrane Database of Systematic Reviews
|August 8, 2014
PubMed
Summary

Praziquantel is the most effective drug for treating urinary schistosomiasis, significantly reducing egg excretion. Further research is needed to explore combination therapies for improved treatment outcomes.

More Related Videos

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni
12:05

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

8.6K
Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
09:58

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Published on: June 5, 2012

13.4K

Related Experiment Videos

Last Updated: Apr 26, 2026

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules
05:30

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

19.8K
Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni
12:05

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

8.6K
Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
09:58

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Published on: June 5, 2012

13.4K

Area of Science:

  • Tropical Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Urinary schistosomiasis, caused by Schistosoma haematobium, leads to chronic inflammation and fibrosis.
  • The condition affects the bladder, causing significant morbidity and long-term complications.
  • Current treatment options require updated efficacy and safety evaluations.

Purpose of the Study:

  • To evaluate the efficacy and safety of drugs used to treat urinary schistosomiasis.
  • To summarize the evidence from randomized controlled trials (RCTs) on antischistosomal drugs.

Main Methods:

  • Searched multiple databases (Cochrane, MEDLINE, EMBASE, LILACS) for RCTs up to May 2014.
  • Included RCTs comparing antischistosomal drugs against placebo, no intervention, or each other.
  • Extracted data on parasitological failure and egg count reduction, assessing risk of bias and evidence quality (GRADE).

Main Results:

  • Praziquantel (40 mg/kg) significantly reduced egg excretion by approximately 60% compared to placebo (high-quality evidence).
  • Mean egg counts decreased by over 95% with praziquantel treatment.
  • Metrifonate showed marginal improvement over placebo, and combination therapies require further investigation due to inconsistent results.

Conclusions:

  • Praziquantel (40 mg/kg) is the most studied and evidence-based drug for urinary schistosomiasis.
  • Combination therapies (e.g., praziquantel with metrifonate or antimalarials like artesunate) show potential but need rigorous trials.
  • Standardized outcome measures and adequately powered trials are crucial for evaluating new treatment strategies.